Title:
PAC1 ANTIBODIES AND USES THEREOF
Document Type and Number:
Japanese Patent JP2023116808
Kind Code:
A
Abstract:
To provide antibodies that specifically bind to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and potently inhibit its biological activity.SOLUTION: The present invention is based, in part, on the design and generation of high affinity antibodies that specifically bind to and potently inhibit human PAC1. The antibodies of the invention have enhanced inhibitory potency against human PAC1 compared to previously described anti-PAC1 antibodies, with IC50 values in the picomolar range. The isolated antibodies and antigen-binding fragments thereof can be used to inhibit, interfere with, or modulate the biological activity of human PAC1, including inhibiting or reducing PACAP-induced activation of PAC1, inhibiting or reducing vasodilation, and ameliorating or treating symptoms of migraine and other vascular headaches.SELECTED DRAWING: Figure 1A
Inventors:
NEERAJ JAGDISH AGRAWAL
IRWIN CHEN
SU CHONG
BRYNA FUCHSLOCHER
KEVIN GRAHAM
AGNES EVA HAMBURGER
MARK LEO MICHAELS
CHRISTOPHER MOHR
DEREK E PIPER
KENNETH WILLIAM WALKER
WANG ZHULUN
XU CEN
IRWIN CHEN
SU CHONG
BRYNA FUCHSLOCHER
KEVIN GRAHAM
AGNES EVA HAMBURGER
MARK LEO MICHAELS
CHRISTOPHER MOHR
DEREK E PIPER
KENNETH WILLIAM WALKER
WANG ZHULUN
XU CEN
Application Number:
JP2023103312A
Publication Date:
August 22, 2023
Filing Date:
June 23, 2023
Export Citation:
Assignee:
AMGEN INC
International Classes:
C12N15/13; A61K31/4045; A61K31/48; A61K38/02; A61K39/395; A61K45/00; A61P25/04; A61P25/06; A61P43/00; C07K16/28; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/63; C12P21/08
Attorney, Agent or Firm:
Shusaku Yamamoto
Natsuki Morishita
Natsuki Morishita
Previous Patent: Payment system and payment method
Next Patent: Piping structure and its manufacturing method
Next Patent: Piping structure and its manufacturing method